You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

Capivasertib - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for capivasertib and what is the scope of patent protection?

Capivasertib is the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Capivasertib has eighty-eight patent family members in forty-three countries.

One supplier is listed for this compound.

Summary for capivasertib
International Patents:88
US Patents:8
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 23
Patent Applications: 724
What excipients (inactive ingredients) are in capivasertib?capivasertib excipients list
DailyMed Link:capivasertib at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for capivasertib
Generic Entry Date for capivasertib*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for capivasertib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Taiwan University HospitalPhase 2
VA Office of Research and DevelopmentPhase 2
Quotient SciencesPhase 1

See all capivasertib clinical trials

US Patents and Regulatory Information for capivasertib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca TRUQAP capivasertib TABLET;ORAL 218197-002 Nov 16, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Astrazeneca TRUQAP capivasertib TABLET;ORAL 218197-002 Nov 16, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Astrazeneca TRUQAP capivasertib TABLET;ORAL 218197-002 Nov 16, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Astrazeneca TRUQAP capivasertib TABLET;ORAL 218197-002 Nov 16, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Astrazeneca TRUQAP capivasertib TABLET;ORAL 218197-001 Nov 16, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for capivasertib

Country Patent Number Title Estimated Expiration
Hong Kong 1206337 -氨基- -氯苯基 -羥丙基 -吡咯並 嘧啶- -基 哌啶- -甲酰胺的晶型 (CRYSTALLINE FORMS OF (S)-4-AMINON-(1-(4-CHLOROPHENYL)-3- HYDROXYPROPYL)-1-(7H -PYRROLO[2, 3-D]PYRIMIDI N-4-YL) PIPERIDINE-4- CARBOXAMIDE (S)-4--N-(1-(4-)-3-)-1-(7H-[23-D]-4-) -4-) ⤷  Sign Up
Hong Kong 1110503 ORTHO-CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G.PURINES) AS PROTEIN KINASES INHIBITORS ⤷  Sign Up
Denmark 2272517 ⤷  Sign Up
Chile 2008003023 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2006046024 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for capivasertib

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2201012 C02201012/01 Switzerland ⤷  Sign Up PRODUCT NAME: CAPIVASERTIBUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 69300 19.03.2024
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.